Welcome to Carapinha & Consultants.

We are a Specialist Market Access Firm improving patient access through stronger pharmaceutical markets.

Webinar: “Remove barriers to entry by embracing an access-based approach to marketing”

19 May

We’ve joined eyeforpharma as their Strategic Partner to bring you a free webinar: “Remove barriers to entry by embracing an access-based approach to marketing” on Tuesday 26th May 2:30-3:30 pm SAST. Pharma companies in South Africa have products with compelling economic value propositions, however reimbursement constraints have limited the up-take and patient access to new therapies. But how do we […]

China’s medicine pricing pro-market reforms

07 May

China’s National Development and Reform Commission announced earlier this week it would lift medicine price restrictions on most medicines except narcotics and psychotropics. The decision will shift price-setting decisions from regulators to the market and the Commission hopes it will improve competition and result in lower medicine prices. It is still early days whether this policy […]

Single Exit Price Legislation: A Source of Harm to Competition

07 May

Background At the time of formulating the Single Exit Price legislation in South Africa; medicine price inflation, medicine price transparency, and medicine price uniformity were all significant problems in an unregulated medicines market. Medicines price inflation was in the double digits during the 1990s and early 2000’s; it was impossible to determine the true price […]

Dr. Motsoaledi’s meanderings through a Budget Speech, Department of Health

06 May

Dr. Aaron Motsoaledi delivered the Department of Health budget speech on 5 May 2015 and from the get-go focused on the 3 core priorities that: …determine whether the country goes forward or backwards… They included i) the implementation of NHI, ii)  Competition Commission’s Public Market Inquiry (PMI) into the cost of Private Health Care, and […]

Mori and Robberstad paper on pharmacoeconomics in Tanzania

19 Oct

Amani Thomas Mori and Bjarne Robberstad’s paper on pharmacoeconomics in Tanzania is a great contribution. In part, it addresses a generally held hypothesis that pharmacoeconomic studies are impossible in Tanzania and comparable countries because no data is available with which to conduct such analyses. Mori et al clearly demonstrate that researchers have overcome data barriers […]